IDH1 and neoplasm: The 2016 WHO classification of central nervous tumors first introduced molecular parameters to define GBM tumor entities, preserved two (GC-GBM and GSM) variants under the umbrella of isocitrate dehydronase (IDH)-wild type GBM.